News

NATROX® US Randomized Control Trial (RCT) submitted for publication

The NATROX® Oxygen Wound Therapy US Randomized Control Trial (RCT) has now been submitted for publication, following data analysis. The trial focused on non-healing diabetic foot ulcers (DFUs) and primarily evaluated the impact of continuous topical oxygen on healing outcomes when compared to best practice standard of care. With well over 100 patients completing the full 12 week therapy period, this study is expected to become a key paper supporting the use of continuous topical oxygen therapy in non-healing DFUs.

Read More
Jane Clark, VP Global Marketing & Clinical Affairs, in Top 25 Women Leaders in Medical Devices 2021

January 28, 2021
NATROX® O₂ Wins the “Best Wearable Tech in Health Care” Award

December 08, 2020
Inotec AMD Expands Global Headquarter Office in Cambridge, UK

November 16, 2020
Craig Kennedy, Inotec AMD, included in the 10 Best Inspiring CEOs of 2020

October 06, 2020
NATROX® O₂ Featured at International Scientific Conference

September 14, 2020
Dr. Harikrishna KR Nair initiates a NATROX® O₂ Clinical Trial in Malaysia

June 24, 2020
National Institute for Health and Care Excellence (NICE) briefing on NATROX®

April 07, 2020
Inotec Receives Federal Supply Schedule (FSS) award

March 02, 2020
MedTech Business Inotec AMD secures £7 VC Injection

February 18, 2020